抗逆转录病毒药物转换的频率和原因与特定的抗逆转录病毒药物联合治疗：SWITCH 研究。

The frequency and reasons for antiretroviral switching with specific antiretroviral associations: the SWITCH study.

机构信息

St. Stephen's Centre, Chelsea and Westminster Hospital Trust, United Kingdom.

出版信息

Antiviral Res. 2010 May;86(2):227-9. doi: 10.1016/j.antiviral.2010.03.001. Epub 2010 Mar 6.

DOI:10.1016/j.antiviral.2010.03.001

PMID:20211651

Abstract

BACKGROUND

We investigated the reasons for switching antiretroviral regimens, an issue rarely addressed in cohort studies.

METHODS

An observed toxicity switch rate (OTSR) was calculated by Poisson regression using the number of days individuals received each individual antiretroviral drug.

RESULTS

Of 3333 individuals receiving HAART, a total of 14% of regimens were switched, the majority occurring after 6 months of therapy. Toxicity was the major reason for switching (61%) and there were no major statistically significant differences in OTSR between the protease inhibitor (OTSR 26.4, 95% CI 18.3-37) and non-nucleoside reverse transcriptase inhibitor (OTSR 22.2, 95% CI 13.6-34.4) based regimes. For individual antiretrovirals, stavudine and zidovudine had significantly higher "switch" scores than all other drugs.

CONCLUSIONS

There were no differences between the major HAART classes in OTSR. We suggest that newer antiretrovirals will require differentiation in terms of longer-term toxicity, as this is the major reason for switching.

摘要

背景

我们研究了转换抗逆转录病毒治疗方案的原因，这是队列研究中很少涉及的问题。

方法

使用泊松回归计算观察到的毒性转换率（OTSR），该方法使用个体接受每种抗逆转录病毒药物的天数进行计算。

结果

在接受 HAART 的 3333 名个体中，共有 14%的治疗方案发生了转换，大多数转换发生在治疗 6 个月后。毒性是转换的主要原因（61%），在蛋白酶抑制剂（OTSR 26.4，95%CI 18.3-37）和非核苷类逆转录酶抑制剂（OTSR 22.2，95%CI 13.6-34.4）方案之间，OTSR 之间没有统计学上显著的差异。对于个别抗逆转录病毒药物，司他夫定和齐多夫定的“转换”评分明显高于所有其他药物。